Company Overview and News


Add NVS
to your dashboard

Headline News

Your Daily Pharma Scoop: Eiger Selloff, Novartis' Cosentyx, RXi Outlines Business Strategy

14m seekingalpha
Today we will discuss the results from the phase 2 LIBERTY Study announced by clinical stage biopharmaceutical company, Eiger Biopharmaceuticals (EIGR). (62-0)

Merck: Elucidating The Ramifications Of The Recent Keynote Findings

5h seekingalpha
Phase 3 Keynote-189 trial that investigated Keytruda (in combos with either cisplatin or carboplatin) for the 1st-line Rx of patients with metastatic non-small cell lung cancer ("NSCLC") posted positive outcomes. (61-0)

3 Biotech Stocks Start Healthy in '18: Will the Rally Last?

16h zacks
In 2018, the biotech industry is expected to witness a continuation of last year’s favorable trends. Last year, the industry benefited from a number of FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strength in some legacy products. There were some first-time approvals for innovative/game-changing treatment options. (89-1)

Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?

22h zacks
Shares of Puma Biotechnology, Inc. (PBYI - Free Report) have significantly outperformed the industry in a year. The stock has skyrocketed 186.4% compared with the industry’s increase of 3.3% during the period. (52-0)

Novartis (NVS) Announces Acceptance of Humira BLA by the FDA

23h zacks
Novartis AG (NVS - Free Report) generic arm, Sandoz announced that the FDA accepted its Biologics License Application (BLA) for the proposed biosimilar of AbbVie, Inc. (ABBV - Free Report) Humira. (205-0)

3 Pharma and Biotech Stocks to Watch Out for in 2018

2018-01-15 zacks
2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE ARCA Pharmaceutical index gaining 18.7% and 11.8%, respectively. Although the industry continued to face headwinds in the form of drug pricing scrutiny, pricing pressure, increasing competition, concerns regarding Amazon’s interest in entering the healthcare arena, fewer-than-expected acquisition deals and major pipeline setbacks, there were some positive developments as well. (94-0)

Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion

2018-01-15 zacks
GlaxoSmithKline plc (GSK - Free Report) received approval from the FDA’s Center for Biologics Evaluation and Research for the label expansion of influenza vaccine — FluarixQuadrivalent. The vaccine has been approved for infants six months or older.  (59-0)

Your Daily Pharma Scoop: Lipocine's Gloomy Future, Puma Labeling Change, Concert's Mixed Day

2018-01-13 seekingalpha
Puma plans to modify labeling in its European marketing application for its breast cancer candidate neratinib. (254-4)

Analysis: Drugmakers see a pricing blueprint in an $850,000 gene therapy

2018-01-13 in.reuters
SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Drugmakers see a pricing blueprint in an $850,000 gene therapy

2018-01-12 reuters
SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Drugmakers see a pricing blueprint in an US$850,000 gene therapy - Channel NewsAsia

2018-01-12 channelnewsasia
SAN FRANCISCO: Global drugmakers are looking to a tiny biotech's US$850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Incyte: Low Expectations, Great Growth, Looks Appealing

2018-01-12 seekingalpha
The combination of rapid growth and a 40% pullback from 2017 highs creates sales multiples that have collapsed. (13-0)

Ligand (LGND) Inks Deal With Glenmark for OmniAb Platform

2018-01-12 zacks
Ligand Pharmaceuticals Incorporated (LGND - Free Report)  announced that it has inked a worldwide license agreement with global innovative pharmaceutical company, Glenmark Pharmaceuticals. Per the agreement, Glenmark will be able to use the full OmniAb platform for producing mono- and bispecific human therapeutic antibodies. (15-0)

Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod

2018-01-12 zacks
Eli Lilly and Company's (LLY - Free Report) animal health subsidiary, Elanco, and partner Aratana Therapeutics, Inc. (PETX - Free Report) have together announced that their veterinary medicine, Galliprant (grapiprant tablets), has been granted a marketing authorization in the EU for the treatment of pain associated with mild to moderate osteoarthritis (OA) in dogs. (71-0)

Best Index Funds For 2018

2018-01-12 seekingalpha
This article contains some of the best passively managed funds you can add to your portfolio. (71-0)

CUSIP: 66987V109